| Publications | PubMed=7175440; DOI=10.1084/jem.156.6.1755; PMCID=PMC2186870
Alan N. Houghton, Magdalena Eisinger, Anthony P. Albino, J. Gregory Cairncross, Lloyd John Old;
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.
J. Exp. Med. 156:1755-1766(1982) PubMed=6864164; DOI=10.1084/jem.158.1.53; PMCID=PMC2187084
Alan N. Houghton, Hannah Brooks, Richard J. Cote, Michael C. Taormina, Herbert Friedrich Oettgen, Lloyd John Old;
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.
J. Exp. Med. 158:53-65(1983) PubMed=2983346; DOI=10.1073/pnas.82.5.1470; PMCID=PMC397284
Nicholas C. Dracopoli, Alan N. Houghton, Lloyd John Old;
Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity.
Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985) PubMed=2453881; DOI=10.1073/pnas.85.11.3965; PMCID=PMC280341
Francisco X. Real, Keiko S. Furukawa, Michael Jules Mattes, Sara-Ann Gusik, Carlos Cordon-Cardo, Herbert Friedrich Oettgen, Lloyd John Old, Kenneth Oliver Lloyd;
Class 1 (unique) tumor antigens of human melanoma: identification of unique and common epitopes on a 90-kDa glycoprotein.
Proc. Natl. Acad. Sci. U.S.A. 85:3965-3969(1988) PubMed=7509835; DOI=10.1111/1523-1747.ep12371784
Brigitte Bouchard, Setaluri Vijayasaradhi, Alan N. Houghton;
Production and characterization of antibodies against human tyrosinase.
J. Invest. Dermatol. 102:291-295(1994) PubMed=7747814; PMCID=PMC1869278
Nelleke A. Gruis, Jane M. Weaver-Feldhaus, Qing-Yun Liu, Cheryl Frye, Rosalind Eeles, Irene Orlow, Louis Lacombe, Veronica Ponce-Castaneda, Pilar Lianes, Esther Latres, Mark Henry Skolnick ...Show all 13 authors... , Carlos Cordon-Cardo, Alexander Kamb; Show fewer authors
Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.
Am. J. Pathol. 146:1199-1206(1995) PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
Graeme J. Walker, Jose F. Flores, J. Michael Glendening, Amy Hsiu-Ti Lin, Isabel D.C. Markl, Jane W. Fountain;
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Genes Chromosomes Cancer 22:157-163(1998) PubMed=9692547; DOI=10.1038/sj.onc.1201881
Hensin Tsao, Xue Zhang, Eric Benoit, Frank G. Haluska;
Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines.
Oncogene 16:3397-3402(1998) PubMed=10766161
Hensin Tsao, Xue Zhang, Kianna Fowlkes, Frank G. Haluska;
Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
Cancer Res. 60:1800-1804(2000) PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x; PMCID=PMC2586668
Hensin Tsao, Vikas Goel, Heng Wu, Guang Yang, Frank G. Haluska;
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
J. Invest. Dermatol. 122:337-341(2004) PubMed=21725359; DOI=10.1038/onc.2011.250; PMCID=PMC3267014
Feng Xing, Yogindra Persaud, Christine A. Pratilas, Barry Stephen Taylor, Manickam Janakiraman, Qing-Bai She, Humilidad F. Gallardo, C. Liu, Taha Merghoub, Blake E. Hefter, Igor Dolgalev ...Show all 19 authors... , Agnes J. Viale, Adriana Heguy, Elisa de Stanchina, David Cobrinik, Gideon Bollag, Jedd D. Wolchok, Alan N. Houghton, David B. Solit; Show fewer authors
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.
Oncogene 31:446-457(2012) PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625; PMCID=PMC4005042
Moriah Heller Nissan, Christine A. Pratilas, Alexis M. Jones, Ricardo Ramirez, Helen Won, Cai-Lian Liu, Shakuntala Tiwari, Li Kong, Aphrothiti J. Hanrahan, Zhan Yao, Taha Merghoub ...Show all 19 authors... , Antoni Ribas, Paul B. Chapman, Rona D. Yaeger, Barry Stephen Taylor, Nikolaus Schultz, Michael F. Berger, Neal Rosen, David B. Solit; Show fewer authors
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Cancer Res. 74:2340-2350(2014) |
|---|
